Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XERAD: Capecitabine + WBRT for Breast Cancer Brain Metastases
NCT00977379Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2009
- Primary completion
- Feb 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Roche. Started Aug 2009; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00977379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977379.